Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease (NCT02402660) | Clinical Trial Compass
By InvitationPhase 2
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
United States160 participantsStarted 2015-08
Plain-language summary
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old.
Funding Source - FDA OOPD
Who can participate
Age range8 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Simplified Inclusion Criteria:
* Male or female between 8 and 70 years old (inclusive), with any visual acuity
* Has a clinical diagnosis of typical autosomal recessive Stargardt macular dystrophy (STGD1)
* Has provided a genetic report indicating at least two ABCA4 disease-causing mutations. When only one ABCA4 disease-causing mutation is reported, sponsor's permission will be required.
* At least one eye (called the "primary study eye") must have at least one well-demarcated area of significantly reduced autofluorescence as imaged by fundus autofluorescence (FAF), have decreased retinal sensitivity as measured by microperimetry, or have maculopathy expected to progress over the duration of the study
* Primary study eye must have clear ocular media and adequate pupillary dilation, including no allergy to dilating eyedrops, to permit good quality retinal imaging
* Healthy as judged by investigator
* Able and willing to comply with study requirements, restrictions and instructions and is likely to complete the 24-month study
* Has signed and dated the informed consent forms (or assent where appropriate) to participate
* Female of childbearing potential has signed the informed consent about birth defects or attestation on contraception requirements
Main Exclusion Criteria:
* Has taken disallowed items (supplement containing vitamin A or beta-carotene, liver-based products, or prescription oral retinoid medications) over the past 30 days
* Is lactating, pregnant, or has a pos…
What they're measuring
1
Safety and tolerability of 24 months of daily dosing of ALK-001 assessed by incidence and/or clinically significant changes of a combination of ocular and non-ocular adverse events